Related Experiment Videos
Successful treatment of gram-negative bacillary meningitis with imipenem/cilastatin
Abstract:
A patient with meningitis caused by a strain of Actinetobacter anitratus that was resistant to all commercially available antibiotics was treated with imipenem/cilastatin administered intravenously in a dose of 1 gm of imipenem every six hours. The minimal inhibitory concentration of imipenem against the isolate was less than or equal to 0.04 micrograms/ml. The patient tolerated the drug well and was cured after 12 days of therapy.
Insights
A patient with meningitis caused by antibiotic-resistant Actinetobacter anitratus was successfully treated with imipenem/cilastatin. This intravenous therapy demonstrated efficacy against a highly resistant bacterial strain, leading to patient recovery.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Meningitis caused by Actinetobacter anitratus presents a significant therapeutic challenge due to emerging antibiotic resistance.
- Conventional antibiotic treatments are often ineffective against multidrug-resistant bacterial strains.
Observation:
- A patient diagnosed with meningitis exhibited infection by an Actinetobacter anitratus strain resistant to all standard antibiotics.
- The specific isolate demonstrated a minimal inhibitory concentration (MIC) for imipenem of less than or equal to 0.04 µg/ml.
Findings:
- Intravenous administration of imipenem/cilastatin at 1 gm every six hours proved effective in treating the resistant infection.
- The patient experienced a complete cure after 12 days of imipenem/cilastatin therapy with good drug tolerance.
Implications:
- Imipenem/cilastatin represents a viable therapeutic option for meningitis caused by carbapenem-resistant Actinetobacter anitratus.
- This case highlights the importance of susceptibility testing and exploring alternative antibiotics for challenging infections.